Shares of Juno Therapeutics Inc (NASDAQ:JUNO) are trading up substantially this afternoon as rumors make their way around social media and trader’s desks that the company could be an acquisition target. Although no specifics have been stated as to what company may be considering acquiring Juno Therapeutics Inc (NASDAQ:JUNO) traders seem to be betting on the likelihood of possible news over the next several days or weeks.
One possible name which has been thrown around as of late when it comes to a possible acquisition of Juno is Celgene Corporation (CELG), although we have not been able to find any solid information linking the two companies. The stock is currently trading higher by 2.00% or $0.9 following the positive news, hitting $45.71 per share at the time of us publishing this article. About 769,280 shares traded hands. JUNO has declined 1.43% since May 12, 2015 and is downtrending. It has outperformed the S&P500 by 2.25%.
From a total of 5 analysts covering Juno Therapeutics Inc (NASDAQ:JUNO) stock, 3 rate it a “Buy”, 0 a “Sell”, and 2 a “Hold”. This means that 60% of the ratings are positive. The highest target price is $73 while the lowest target price is $47.0. The mean of all analyst targets is $60.14 which is 31.57% above today’s ($45.71) stock price. Juno Therapeutics Inc was the topic of 9 analyst reports since July 22, 2015 according to the firm StockzIntelligence Inc. Goldman Sachs initiated shares on November 18 with a “Neutral” rating. Standpoint Research initiated shares with a”Buy” rating and a $47.0 target share price in their report from an August 24. FBR Capital initiated JUNO stock in a recent report from August 18 with a “Outperform” rating.
The institutional sentiment decreased to 0.95 in Q2 2015. It’s down 1.65, from 2.6 in 2015Q2. The ratio turned negative, as 59 funds sold all their Juno Therapeutics Inc shares they owned while 25 reduced their positions. 28 funds bought stakes while 52 increased their total positions. Institutions now own 25.57 million shares which is 25.97% more than the previous share count of 20.30 million in 2015Q2.
Sound Energy Partners Inc. holds 2.12% of its total portfolio in Juno Therapeutics Inc, equating to 25,800 shares. Bb Biotech Ag owns 1.31 million shares representing 1.68% of their total US portfolio. Moreover, Kazazian Asset Management Llc has 0.69% of their total portfolio invested in the company, equating to 13,376 shares. The Maryland-based Rock Springs Capital Management Lp has a total of 0.65% of their portfolio invested in the stock. Turner Investments L.P., a Pennsylvania-based fund reported 69,680 shares owned.
Juno Therapeutics, Inc. is a biopharmaceutical company. The company has a market cap of $4.62 billion. The Firm is developing cell cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells. It currently has negative earnings. Juno’s product candidates, JCAR015, JCAR017 and JCAR014, utilize CAR technology to target CD19, a protein expressed on the surface of various B cell leukemias and lymphomas.